Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijsu.2018.04.056 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open-Label, Single-Arm, Phase IV Study.
Asia Pac J Clin Oncol
September 2025
Roche Products India Pvt. Ltd, Mumbai, India.
Introduction: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single-arm, phase IV study assessed the safety and efficacy of T-DM1 in Indian patients with HER2-positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.
Methods: Patients received T-DM1 (3.
Efficacy of peroneal nerve functional electrical stimulation (FES) for the reduction of bradykinesia in Parkinson's disease: an assessor-blinded randomised controlled trial (STEPS II)-study protocol.
BMJ Open
September 2025
Salisbury NHS Foundation Trust, Salisbury, UK.
Introduction: Difficulty with walking can lead to reduced quality of life for people with Parkinson's disease (pwPD); improving walking is considered a treatment priority. Drug therapies can control PD symptoms; however, pwPD often still experience mobility problems.Functional electrical stimulation (FES) induces movement in weak muscles via external electrical stimulation.
View Article and Find Full Text PDFAdaptation of the Italian Version of the Mealtime Assessment Scale in Pediatric Population (MAS-p).
Dysphagia
September 2025
IRCCS Fondazione Don Carlo Gnocchi Onlus, Via di Scandicci, 269, Florence, 50143, Italy.
Unlike what is observed in the adult population, in paediatric rehabilitation, no reliable and validated observational tools are available in the Italian language to evaluate subjects considered to be at risk for swallowing disorders, regardless of the pathology. The aim of this study was to adapt the Mealtime Assessment Scale (MAS) to a paediatric population. Additionally, internal consistency, intra-rater and inter-rater agreement, concurrent validity and discriminative ability were investigated to assess validity and reliability of the scale.
View Article and Find Full Text PDFNanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma.
Blood
September 2025
University of Virginia Cancer Center, Charlottesville, Virginia, United States.
Histone deacetylase inhibitors (HDACi) are valued treatment options for patients with T-cell malignancies. Romidepsin is a selective Class I HDACi initially approved for patients with relapsed or refractory (R/R) CTCL and PTCL. Romidepsin was withdrawn from its PTCL indication following a negative randomized Phase IV study (Ro-CHOP) that showed no benefit over CHOP alone, further diminishing options for patients.
View Article and Find Full Text PDFThe preclinical discovery and development of gepirone hydrochloride extended-release tablets: the first oral selective 5-HT1A receptor agonist for the treatment of major depressive disorder.
Expert Opin Drug Discov
September 2025
First Department of Psychiatry, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Introduction: Despite advances in antidepressant development, many patients with major depressive disorder (MDD) remain inadequately treated. Gepirone, a selective 5-HT1A agonist without reuptake inhibition, offers a novel mechanism potentially improving efficacy and tolerability over selective serotonin reuptake inhibitors (SSRIs) and earlier agents.
Areas Covered: This case history describes gepirone's discovery and development, including its pharmacodynamic profile, preclinical data on pharmacology, mechanism of action, and effects on depressive-like behavior and anxiety, as well as early clinical findings on its safety and efficacy in major depressive disorder.